Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, randomized, active control study, comparing P1101
monotherapy to entecavir monotherapy in patients with HBeAg-negative chronic hepatitis B
under long-term nucleos(t)ide analogue therapy.